Introduction of Lycium barbarumglycopeptide

枸杞糖肽介绍

It is generally believed that among the authentic medicinal materials of Lycium barbarum, the most active ingredient is Lycium barbarum polysaccharide，whereas Lycium barbarum glycopeptide (LbGp), which is further separated and extracted active ingredients, the bioactivity can reach 1-2 orders of magnitude of Lycium barbarum polysaccharide.

普遍认为，道地药材枸杞子中，活性最高的成分为枸杞多糖，而枸杞糖肽，是进一步分离提取的活性成分，活性可达枸杞多糖的1-2个数量级。

The extraction of LbGp uses organic Lycium barbarum fruit and deionized water (according to the International Organization for Standardization ISO/TC 147, deionized water is pure water after removing impurities in the form of ions). This patented extraction technology can effectively preserve the 3D molecular structure and biological activity of LbGp.

枸杞糖肽提取采用有机枸杞子与去离子水（符合国际标准ISO/TC 147，除去了呈离子形式杂质后的纯水）， 结合专利提取技术能有效地保存提取枸杞糖肽的 3D 分子结构及其生物活性。

During the extraction process, small molecule impurities are removed, including small molecule glycoprotein oligosaccharides (that are known to cause "heat syndrome" problems in Chinese medicine theory). About 100g of Lyciumbarbarum fruit extracts 1g of bioactive LbGp (ie 1%).

在提取过程中，去除了小分子杂质，尤其是其中的小分子糖蛋白寡糖（小分子糖蛋白寡糖是已知引起「热气」问题的小分子）。约 100g 枸杞子中提取到 1g 具有生物活性的枸杞糖肽（即 1%）。

The Pioneer R&D work on Lycium barbarum glycopeptide

枸杞糖肽的原创研发单位

The Shanghai Institute of Organic Chemistry (SIOC), Chinese Academy of Sciences is a comprehensive chemistry research institute integrating basic research, applied research and high-tech innovation research. Founded in May 1950, it was one of the first 15 research institutes established by the Chinese Academy of Sciences. In 2017, Cinda Biopharmaceuticals (Suzhou) Co., Ltd. reached a cooperation agreement with the Institute on the authorization and development of tumor immune targeted small molecule drugs with US$457 million, plus sales commission.

中国科学院上海有机化学研究所(SIOC)是集基础研究、应用研究和高技术创新研究为一体的综合性化学研究机构，创建于1950年5月，是中国科学院首批成立的15个研究所之一。2017年与信达生物制药（苏州）有限公司 以4.57亿美元另加销售提成的合作方式，就肿瘤免疫靶向小分子药物的授权开发达成了合作协议。

The Pioneer R&D team of Lycium barbarum glycopeptide

枸杞糖肽的原创研发团队

The key researcher of LbGp, Professor Tian Gengyuan, was project leader, professor, and supervisor for Ph.D students, of SIOC, Chinese Academy of Sciences. He has obtained 10 scientific and technological achievements and 7 scientific and technological achievements awards, published more than 80 research papers, participated in the compilation of 4 academic books, and obtained 14 invention patents. Since 1985, under the arrangement of the Shanghai Science Commission and the Shanghai Institute of Organic Chemistry of the Chinese Academy of Sciences， his team has been investigating on Lycium barbarum related materials. After more than ten years, the glycoprotein of Lyciumbarbarum was successfully isolated for the first time, named Lyciumbarbarum glycopeptide; and Professor Tian became "The first in Lyciumbarbarum glycopeptide research".

枸杞糖肽主要研发人——田庚元研究员，曾任中国科学院上海有机化学研究所课题组长,研究员,博士生导师。曾获10项科技成果及7项科技成果奖，发表研究论文80多篇,参与编写学术著作4部,获发明专利14项。自1985年起，应上海科委与中国科学院上海有机化学研究所安排，田庚元教授团队开展枸杞相关物质研究，历经十余年首次分离出了枸杞子糖蛋白，命名枸杞糖肽。田庚元研究员成为国内“枸杞糖肽研究第一人”。

At present, Professor Lv Long, and Jiang Yan, senior engineer, and the team at the Institute continues on with the work on Lycium barbarum glycopeptide taking it to further depth.

目前，中国科学院上海有机化学研究所吕龙研究员、江艳高级工程师等科研人员，仍继续着枸杞糖肽的深入研究工作。

SIOC has performed experimentsincluding: mouseretina, spleen cell proliferation, macrophage phagocytosis, in vivo promotion of lymphocyte transformation rate in mouse, regulation of T and B lymphocyte proliferation activity in immunocompromised mouse,mouse-specific antioxidant red blood cell antibody (hemolysin) test, anti-tumor test, anti-lowdensity lipoprotein (LDL) oxidation test,and separation of the variousLbGp components to determine their different functions(immunity and others).

SIOC已完成实验的有：小鼠视网膜实验、脾细胞增殖实验、巨噬细胞吞噬试验、小鼠体内促淋巴细胞转化率实验、对于免疫低下小鼠 T、B 淋巴细胞增殖活性调节的实验、小鼠特异性抗氧红细胞抗体（溶血素）试验、抗肿瘤实验、抗低密度脂蛋白（LDL）氧化作用试验、分离枸杞糖肽各组分测定免疫功能等一系列实验。

Lycium barbarum polysaccharide (LBP) is a research hotspot in recent years pursued by scientists worldwide in many fields. As of August 2021, there are a total of 330 Chinese and English publications on LBP in the treatment/prevention of different diseases with experiments involving: In vivo, in vitro, single-blind and randomized control trial (RCT) studies. Lycium barbarum glycopeptide (LbGp) has attracted more and more attention of scientists due to its higher bioactivity. It has triggered research and application works in the areas of retinitis pigmentosa, glaucoma, depression, adolescent myopia prevention, and stem cells.

枸杞多糖(LBP)是近年来世界多领域科学家追逐的研究热点，截止 2021年 8 月关于枸杞多糖（LBP)在治疗/预防不同病因和系统疾病中发挥作用的中英文文献共计 330 篇，试验涉及体内、体外及单盲、双盲 (RCT) 研究。 枸杞糖肽（LbGp）因其更高的活性，越来越引起科学家们的关注，在视网膜色素变性、青光眼、抑郁症、青少年近视预防、干细胞等领域引发了研究和应用。

Recently, scientists have, for the first time, used LbGp in clinical trials, adopting approved standardized process. Related research results may fill in some blank areas, such as in retina repair, depression, Alzheimer’s disease, etc., LbGp may be used to delay onset of disease process, as preventive measure, or as treatment or supplementary treatment for retina disease, depression, and others.

近期，科学家们首次采用枸杞糖肽(LbGp)，引入规范的临床实验；相关研究成果有可能填补一些空白领域，例如视网膜的修复、抑郁症、阿尔茨海默病等等。枸杞糖肽可能可以延迟疾病初发的时间，预防疾病，或者用以治疗/辅助治疗治疗视网膜疾病、抑郁症、及其他疾病。